No Data
Benign Growth For HARBIN GLORIA PHARMACEUTICALS Co., LTD (SZSE:002437) Underpins Its Share Price
Harbin Gloria Pharmaceuticals (002437.SZ): Currently, there are no plans for a spin-off listing on the Hong Kong stock market.
On December 19, Gelonghui reported that Harbin Gloria Pharmaceuticals (002437.SZ) stated on the investor interaction platform that the company's products, Annao Pills/Tablets, are unique essential pharmaceutical varieties of Traditional Chinese Medicine. The company will increase investment to enhance product competitiveness through improving product qualifications, increasing clinical medication guidelines, and professional academic promotions. Additionally, the company will actively seek differentiated products through independent research and development, cooperative development, mergers and acquisitions, and introduction, continuously enriching the company's product pipeline with high-end generic drugs and distinctive Chinese Patent Medicines, which have technical barriers. The company currently has no plans for a separate listing on the Hong Kong Stock Exchange.
Harbin Gloria Pharmaceuticals (002437.SZ): No plans to repurchase company shares.
Gelonghui, December 2nd | Harbin Gloria Pharmaceuticals (002437.SZ) announced that as of November 30, 2024, the company has not yet repurchased its shares through the dedicated securities repurchase account.
Harbin Gloria Pharmaceuticals (002437.SZ): Director Wang Dongxu has completed a shareholding reduction of 0.21 million shares.
On December 2, Gelonhui reported that Harbin Gloria Pharmaceuticals (002437.SZ) announced that on December 2, 2024, the company received a notification letter on the progress of the shareholding plan issued by Director Mr. Wang Dongxu. Mr. Wang Dongxu's shareholding plan has been fully implemented; he has cumulatively reduced holdings by 0.21 million shares, a reduction rate of 0.0092%.
Do Its Financials Have Any Role To Play In Driving HARBIN GLORIA PHARMACEUTICALS Co., LTD's (SZSE:002437) Stock Up Recently?
Harbin Gloria Pharmaceuticals (002437.SZ): Received special financing support for repurchasing company shares.
Gloria Pharmaceuticals (002437.SZ) announced on October 31 that it has received a "Loan Commitment Letter" from Bank of China Harbin Pingfang Branch, committing to provide the company with a maximum of 70 million RMB of loan funds specifically for share buyback. The obtaining of the aforementioned loan commitment letter can provide financing support for the company's share buyback. The specific loan matters will be subject to the loan contract signed by both parties, and the company will actively implement the share buyback according to the share buyback plan.
The Market Doesn't Like What It Sees From HARBIN GLORIA PHARMACEUTICALS Co., LTD's (SZSE:002437) Revenues Yet As Shares Tumble 27%
